Home › Lung Cancer › NCT07008664
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * 18 years old or older * Patient at University of Maryland Baltimore Washington Medical Center * Willing and able to consent to study procedures listed in the protocol * Ability to speak and understand English Exclusion Criteria: * Younger than 18 years old * Patient not cared for at University of Maryland Baltimore Washington Medical Center * Unable to consent to study procedures listed in the protocol * Unable to speak or understand English
About the study
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future.
Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
What is being tested
- Epigenetic Signature Assay (other)
Sponsor: University of Maryland, Baltimore · Participants: 750 · Started: Mar 31, 2025
Contact the study team
- McKenzie Bedra, MPH · Phone: 410-553-8184
- Jennifer Emel, MA · Phone: 410-553-8048
Official record on ClinicalTrials.gov — NCT07008664
Locations in the U.S.
| Maryland | University of Maryland Baltimore Washington Medical Center, Glen Burnie |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.